Effectiveness and safety of TACROLIMUS (cas 109581-93-3) therapy for myasthenia gravis: A single arm meta-analysis
-
Add time:07/26/2019 Source:sciencedirect.com
To evaluate the effectiveness and safety of TACROLIMUS (cas 109581-93-3) in myasthenia gravis (MG) patients, a systematic review and meta-analysis was performed. Researches published between January 1, 2000 and December 31, 2017 in English language were searched in Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) and clinicaltrials.gov databases. We extracted the outcome measures regarding the dose of glucocorticoids (GC), Myasthenia Gravis Foundation of America (MGFA) quantitative myasthenia gravis score (QMGS), MG activities of daily living (MG-ADL) and serum anti-acetylcholine receptor (AChR) antibody titer in each included study. Among 25 studies involving 633 patients, we observed a mean reduction in GC dose by 1.21 (95% CI, 0.44–1.98), QMGS by 2.02 (95% CI, 0.86–3.18), MG-ADL by 1.21 (95% CI, 0.81–1.62) and serum anti-AChR antibody titer by 0.61 (95% CI, 0.43–0.80), which all reached a statistical significance (p < 0.01). Interestingly, a significant correlation was acquired between the disease duration and the reduction of QMGS (p = 0.033; 95% CI, −0.64 to −0.033). Adverse events (AEs) were recorded in 258 of 633 patients (40.8%) with tacrolimus therapy while most were mild. Our meta-analysis demonstrates that tacrolimus may be a beneficial drug option to treat MG.
We also recommend Trading Suppliers and Manufacturers of TACROLIMUS (cas 109581-93-3). Pls Click Website Link as below: cas 109581-93-3 suppliers
Prev:Conversion From Immediate-Release TACROLIMUS (cas 109581-93-3) to Prolonged-Release TACROLIMUS (cas 109581-93-3) in Stable Heart Transplant Patients: A Retrospective Study
Next:Inhibitory effect of immunosuppressive drug TACROLIMUS (cas 109581-93-3) on voltage-gated K+ current in rabbit coronary arterial smooth muscle cells) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Comparison of anti-atopic dermatitis activities between DHMEQ and TACROLIMUS (cas 109581-93-3) ointments in mouse model without stratum corneum07/31/2019
- An open-label, randomized trial indicates that everolimus with TACROLIMUS (cas 109581-93-3) or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients07/30/2019
- Relationships between concomitant biologic DMARDs and prednisolone administration and blood TACROLIMUS (cas 109581-93-3) exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients07/29/2019
- Recipient ABCB1, donor and recipient CYP3A5 genotypes influence TACROLIMUS (cas 109581-93-3) pharmacokinetics in liver transplant cases07/28/2019
- Inhibitory effect of immunosuppressive drug TACROLIMUS (cas 109581-93-3) on voltage-gated K+ current in rabbit coronary arterial smooth muscle cells07/27/2019
- Conversion From Immediate-Release TACROLIMUS (cas 109581-93-3) to Prolonged-Release TACROLIMUS (cas 109581-93-3) in Stable Heart Transplant Patients: A Retrospective Study07/25/2019
- A sample processing method for immunoassay of whole blood TACROLIMUS (cas 109581-93-3)07/24/2019
- Therapeutic drug monitoring of cyclosporine and TACROLIMUS (cas 109581-93-3) in Myanmar kidney transplant patients07/23/2019
- TACROLIMUS (cas 109581-93-3) ointment in the management of atopic keratoconjunctivitis07/22/2019